Crinetics Pharmaceuticals (CRNX)
NASDAQ:CRNX
Want to see CRNX full AI Analyst Report?
Earnings Data
Report Date
Aug 07, 2026TBA (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
-1.22Last Year’s EPS
-1.23Same Quarter Last Year
Strong Buy
Based on 10 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call communicated a strong early commercial launch for Palsonify with meaningful patient additions, encouraging reimbursement progress (≈70% reimbursed, >60% coverage), expanding prescriber footprint and robust pipeline advancement, all supported by a strong balance sheet. Offsetting these positives are elevated and rising R&D and operating expenses, limited disclosure of certain commercial conversion metrics, a remaining reimbursement gap (~30% of patients), appointment‑driven adoption constraints, and no firm timelines provided for several key pivotal readouts or international revenue. On balance, the positives around launch momentum, payer traction, prescriber growth and cash runway outweigh the operational and disclosure limitations.Company Guidance
Strong Early Commercial Launch
Palsonify generated $10.3M in net product revenue (total revenue $10.7M including $0.4M license) in Q1 and added 232 new patient enrollment forms during the quarter, demonstrating early commercial traction.
Rapid Reimbursement and Coverage Progress
Approximately 70% of patients on therapy at the end of Q1 were reimbursed and the company has achieved over 60% coverage overall, remaining on track to exceed its 75% coverage goal by the end of Q3 2026.
Increase in Treatment‑Naive Prescriptions
Treatment‑naive patients rose from 5% in Q4 2025 to 15% in Q1 2026 (a +10 percentage point change; 3x the prior share), signaling growing physician confidence and early first‑line adoption.
Expanding Prescriber Base and Market Reach
Unique prescribers grew to 263 as of March 31 (up from >125 at end of 2023, >110% increase), with prescriptions split roughly 50/50 between academic and community settings and an identified patient pool of approximately 1,400 across prescribers.
Robust Clinical and Scientific Momentum
Four major clinical trials are actively running/recruiting (including atumelnant Phase III COLMCAH and Phase II/III BALANCE pediatric), 9682 is in dose escalation, and multiple oral presentations/publications (including PATHFNDR-1 indirect comparison) reinforce efficacy and payer dialogue.
Compelling Efficacy Data Supporting Value Proposition
PATHFNDR-1 indirect comparison reported placebo‑adjusted IGF‑1 normalization of 79.7% with paltusotine—more than double reported results for comparator therapies—plus rapid onset of action in 2–4 weeks and strong symptom control, which is driving payer interest and earlier formulary wins.
Strong Balance Sheet and Runway
Crinetics ended the quarter with approximately $1.3B in cash, cash equivalents and investments and projects this funding will support operations into 2030, enabling continued commercialization and multiple pivotal readouts.
Maintained 2026 Expense Guidance
Management is maintaining 2026 guidance for GAAP operating expenses of $600M–$650M and non‑GAAP operating expenses of $480M–$520M, providing visibility into planned resource allocation.
CRNX Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
CRNX Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 07, 2026 | $43.49 | $37.48 | -13.82% |
Feb 26, 2026 | $43.74 | $41.10 | -6.04% |
Nov 06, 2025 | $43.49 | $40.00 | -8.02% |
Aug 07, 2025 | $27.88 | $26.85 | -3.69% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Crinetics Pharmaceuticals (CRNX) report earnings?
Crinetics Pharmaceuticals (CRNX) is schdueled to report earning on Aug 07, 2026, TBA (Confirmed).
What is Crinetics Pharmaceuticals (CRNX) earnings time?
Crinetics Pharmaceuticals (CRNX) earnings time is at Aug 07, 2026, TBA (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is CRNX EPS forecast?
CRNX EPS forecast for the fiscal quarter 2026 (Q2) is -1.22.